Quest Diagnostics Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Quest Diagnostics Incorporated DGX is expected to release earnings results for its fourth quarter, before the opening bell on Feb. 1, 2024.

Analysts expect the company to report quarterly earnings at $2.11 per share, up from year-ago earnings of $1.98 per share. The company is projected to report revenue of $2.25 billion, compared to $2.33 billion in the year-earlier quarter, according to data from Benzinga Pro.

Fitbit and Quest Diagnostics announced a collaboration to advance research on the use of wearable devices to improve metabolic health.

Quest Diagnostics shares fell 0.3% to close at $128.43 on Wednesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

• Truist Securities analyst David Macdonald maintained a Hold rating and increased the price target from $145 to $150 on Dec. 20, 2023. This analyst has an accuracy rate of 68%.
• B of A Securities analyst Derik De Bruin upgraded the stock from Neutral to Buy and boosted the price target from $140 to $160 on Dec. 12, 2023. This analyst has an accuracy rate of 76%.
• Citigroup analyst Patrick Donnelly maintained a Neutral rating and raised the price target from $130 to $145 on Dec. 11, 2023. This analyst has an accuracy rate of 68%.
• UBS analyst Kevin Caliendo maintained a Neutral rating and increased the price target from $135 to $137 on Dec. 7, 2023. This analyst has an accuracy rate of 75%.
• JP Morgan analyst John Stansel maintained a Neutral rating and raised the price target from $148 to $149 on Nov. 17, 2023. This analyst has an accuracy rate of 68%.

Read This Next: $16.5M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying